Sterofounded In 2017 And Headquartered In Israelis A Clinical Stage Company Committed To The Research And Development Of Novel And Improved Cannabidiolcbdbased Treatment Solutions That Will Potentially Benefit Millions Of Patients By Reducing The Side Effects And The Need Of Steroid Therapy Stero Sextremely Wide Coverage Patentcbd From Any Sourcein Any Combinationany Dosagein Any Delivery Systemall For More Than 130 Diseases By Namewas Issued In The Us On August 2018 And Is Pending In Main Countries Around The Worldstero Currently Has 3 Ongoing Clinical Trials2 Phase 2A Clinical Trials In Crohn S Diseaseand In Chronic Urticariahives 1 Phase 1 2 Clinical Trial Treating Severe Covid 19 Patientsall Covered By Stero S Ip & Pursuing The Fda Drug Routewith More In The Pipeline
